Ocugen, Inc. Logo

Ocugen, Inc.

Develops gene/cell therapies and vaccines, specializing in blindness and public health.

OCGN | NDAQ

Overview

Corporate Details

ISIN(s):
US43358V1098 (+1 more)
LEI:
Country:
United States of America
Address:
11 GREAT VALLEY PARKWAY, 19355 MALVERN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company is a pioneer in developing treatments for blindness diseases, leveraging its breakthrough modifier gene therapy platform to address significant unmet medical needs in inherited retinal diseases. Ocugen's development pipeline also extends to vaccines and other biologics aimed at improving public health. The company operates with a patient-centric mission to deliver innovative therapeutic solutions for conditions with limited or no available treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ocugen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ocugen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ocugen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan 4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan 6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan 4978
RESEARCH FRONTIERS INC Logo
Develops and licenses smart glass tech for instant light, UV, and heat control.
United States of America REFR
Resolute Holdings Management, Inc. Logo
Asset management firm acquiring and operationally enhancing companies for long-term growth.
United States of America RHLD
Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.
Japan 4591
Rise Consulting Group, Inc. Logo
Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.
Japan 9168
ROQUEFORT THERAPEUTICS PLC Logo
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
United Kingdom ROQ
ROSS GROUP PLC Logo
A holding company in liquidation, formerly providing supply chain management & technology solutions.
United Kingdom RGP

Talk to a Data Expert

Have a question? We'll get back to you promptly.